Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumicitabine long-term follow-up after RSV infection
2016-002095-26Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in respiratory syncytial virus disease (RSV) comparing Prior lumicitabine with Prior placebo (2 arms). Primary endpoint: Clinical diagnosis of asthma within 2 years after RSV infection. Started Aug 2017; status: completed.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2016-002095-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002095-26.